血清CEA、NSE、PTN水平检测诊断早期肺癌的应用价值  

Detection of Serum CEA,NSE and PTN Levels in Early Diagnosis of Lung Cancer

作　　者：李馥郁 田春艳 李淘淘 LI Fuyu;TIAN Chunyan;LI Taotao(Department of General Oncology,Qinhuangdao Fourth Hospital,Qinhuangdao,Hebei,China,066000;Medical Department of Qinhuangdao Fourth Hospital,Qinhuangdao,Hebei,China,066000)

机构地区：[1]秦皇岛市第四医院综合肿瘤科,河北秦皇岛066000 [2]秦皇岛市第四医院医务科,河北秦皇岛066000

出　　处：《分子诊断与治疗杂志》2022年第3期479-482,共4页Journal of Molecular Diagnostics and Therapy

基　　金：秦皇岛市重点研发计划科技支撑项目(202004A043)。

摘　　要：目的探讨联合检测血清癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、人多效蛋白(PTN)联合应用诊断肺癌的临床价值。方法选取秦皇岛市第四医院2019年3月至2021年8月确诊的肺癌患者100例(肺癌组)、肺部良性肿瘤患者40例(良性组)、体检志愿者40例作为对照组,检测三组患者血清CEA、NSE、PTN水平,并分析不同病理学类型、TNM分期、分化程度肺癌患者血清CEA、NSE、PTN水平的差异,并以病理学结果作为金标准计算三种指标单独及联合应用鉴别诊断肺癌的临床价值。结果肺癌组患者的血清CEA、NSE、PTN水平均显著高于良性组和对照组,差异具有统计学意义(P<0.05);肺腺癌与肺鳞癌患者的血清CEA、NSE、PTN水平差异无统计学意义(P>0.05);低分化、Ⅲ期+Ⅳ期肺癌患者的血清CEA、NSE、PTN水平显著高于高中分化、Ⅰ期+Ⅱ期肺癌患者,差异具有统计学意义(P<0.05);血清CEA鉴别诊断肺癌的AUC为0.689、灵敏度为57.00%、特异度为75.00%;NSE鉴别诊断肺癌的AUC为0.647、灵敏度为45.00%、特异度为80.00%;PTN鉴别诊断肺癌的AUC为0.616、灵敏度为60.00%、特异度为62.50%。血清CEA、NSE、PTN联合应用鉴别诊断肺癌的AUC为0.841、灵敏度为74.00%、特异度为85.00%。结论血清CEA、NSE、PTN联合应用鉴别诊断肺癌具有较高的临床价值。Objective To explore the clinical value of combined detection of serum carcinoembryonic antigen(CEA),neuron specific enolase(NSE),and human multiple protein(PTN)for the diagnosis of lung cancer.Methods A total of 100 lung cancer patients(lung cancer group),40 patients with benign lung tumors(benign group),and 40 physical examination volunteers who were diagnosed in the Fourth Hospital of Qinhuangdao City from March 2019 to August 2021 were selected as the control group,and the two groups were tested.Serum CEA,NSE and PTN levels of patients were analyzed,and the differences in serum CEA,NSE and PTN levels of lung cancer patients with different pathological types,TNM stages,and differentiation degrees were analyzed,and the pathological results were used as the gold standard to calculate the three indicators alone or in combination to identify Clinical value in the diagnosis of lung cancer.Results The serum levels of CEA,NSE and PTN in patients with lung cancer were significantly higher than those in benign group(P<0.05).There was no significant difference in serum CEA,NSE and PTN levels between lung adenocarcinoma and lung squamous cell carcinoma(P>0.05).Serum CEA,NSE,and PTN levels in patients with poorly-differentiated and stageⅢ+Ⅳlung cancer were significantly higher than those in patients with welldifferentiated,stageⅠ+Ⅱlung cancer patients(P<0.05).The AUC,sensitivity and specificity of serum CEA in differential diagnosis of lung cancer were 0.689,57.00%and 75.00%respectively.The AUC,sensitivity and specificity of NSE in differential diagnosis of lung cancer were 0.647,45.00%and 80.00%respectively.The AUC,sensitivity and specificity of PTN in differential diagnosis of lung cancer were 0.616,60.00%and 62.50%respectively.The AUC,sensitivity and specificity of serum CEA,NSE and PTN combined in differential diagnosis of lung cancer were 0.841,74.00%and 85.00%respectively.Conclusion The combined application of serum CEA,NSE and PTN in differential diagnosis of lung cancer has high clinical value.

关 键 词：癌胚抗原 神经元特异性烯醇化酶 人多效蛋白 肺癌 

分 类 号：R734.2[医药卫生—肿瘤]